Efavirenz: resistance and cross-resistance.
Resistant strains, the major cause of treatment failure in the management of HIV infection, evolve whenever virus replication is incompletely suppressed by drug therapy. In such cases, genotypic analysis of proviral DNA or phenotypic analysis of viral isolates or recombinant molecular clones can provide useful information for the clinician. With regard to NNRTIs, a single mutation at K103N is the most predominant resistance RT mutation observed with the NNRTIs and confers cross-resistance between efavirenz, nevirapine and delavirdine. K103N is found in HIV strains isolated from patients experiencing a viral rebound in plasma HIV-RNA levels who have received an efavirenz-containing regimen. Phenotypic analysis showed that the K103N mutation alone confers an approximate 20-fold increase in the IC50 of efavirenz.
Clotet
B
B
Hospital Universitari Germans Trias I Pujol, Badalona, Spain.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D003521:Cyclopropanes; D020008:Delavirdine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation; D019829:Nevirapine / Q000627:therapeutic use; D010078:Oxazines / Q000627:therapeutic use*; D010641:Phenotype; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D017211:Treatment Failure; D014779:Virus Replication
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D020008:Delavirdine; C098320:efavirenz